Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

POXEL | 4,569 followers on LinkedIn. Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1).

CoFounder & COO Poxel

Sebastien Bolze

CEO Poxel

Thomas Kuhn

Principal Data Manager/ Data Team Lead

Cécilia Bergounioux

LLC at POXEL

maz ony

POXEL

Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update: ➡️ TWYMEEG® sales continue to increase in Japan for the last quarter (July-September) by 5% over the prior quarter and by 23% over the 3rd quarter 2023 ➡️ Poxel expects TWYMEEG® net sales in Japan in the near term to reach at least JPY 5 billion (EUR 30.6 million) entitling the Company to receive 10% royalties on all TWYMEEG® net sales and a sales-based payment of JPY 500 million (EUR 3.1 million) ➡️ Continued discussions with potential partners in parallel of reviewing the clinical development strategy for PXL770 and PXL065 for the treatment of multiple rare diseases ➡️ As of September 30, 2024, cash and cash equivalents were EUR 13.1 million (USD 14.7 million) ➡️ Following the non-dilutive financing agreement with OrbiMed, cash runway extension until end of 2025, including the full residual drawdown of the equity-linked financing facility put in place with IRIS For more info, read the press release: https://lnkd.in/epSyr2vS

Poxel announces its results for the year 2023 and provides corporate update: ➡️ Agreement with OrbiMed to monetize a portion of TWYMEEG® Royalties for USD 50 million in the form of bonds issuance ➡️ In return OrbiMed to obtain the royalties received by Poxel from sales by Sumitomo Pharma of TWYMEEG® in Japan for a total amount of USD 100 million ➡️ Proceeds from the OrbiMed’s bonds issuance will be used to reduce the Company's debt towards IPF Partners and the PGE banks and to support its strategic plan in rare diseases, while pursuing partnership discussions for its products ➡️ Following the non-dilutive financing agreement with OrbiMed, cash runway extension until end of 2025, including the full residual drawdown of the equity-linked financing facility put in place with IRIS For more information, read the press release: https://lnkd.in/eZzDc8Jn

𝗪𝗘𝗕𝗜𝗡𝗔𝗥 - 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗙𝘂𝗹𝗹 𝗬𝗲𝗮𝗿 𝟮𝟬𝟮𝟯 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 📊 Poxel's management is pleased to invite you to a webinar to present the financial results for Full Year 2023 and to provide corporate update. 🗓️ Thursday, October 3, 2024 🕑 French webinar: 6:00 p.m (CEST) 🕙 English webinar: 7:15 p.m. (CEST) 🇫🇷 To register at the french webinar: https://lnkd.in/ewPTUvAE 🇺🇸 To register at the English webinar: https://lnkd.in/eR4isYAt

Poxel's management is pleased to invite you to a webinar to introduce the Royalty monetization agreement based on TWYMEEG® sales with OrbiMed 🔔 🗓 Monday, September 30, 2024 🕒 2:45 p.m CEST (8:45 a.m ET) Register: https://lnkd.in/eGUn6H-S

Thomas Kuhn , CEO, is pleased to introduce the Royalty monetization agreement based on TWYMEEG® sales with OrbiMed 🎙 For more info, read the press release: https://lnkd.in/eUfCaCfJ

Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update: ➡️ TWYMEEG® sales in Japan for Q2 (April-June) increased 62% vs. the prior quarter (January-March) ➡️ Exclusive discussions being finalized with a leading investor to monetize royalties from sales of TWYMEEG® (Imeglimin) in Japan ➡️ As of June 30, 2024, cash and cash equivalents amounted to EUR 2.8 million (USD 3 million) ➡️ Cash horizon estimated to be sufficient until the completion of the contemplated transaction on monetization of royalties, including only the tranches already drawn down or fully available under the equity-linked financing facility with IRIS For more information, read the press release: https://lnkd.in/e4DTZFXb

Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting: ➡️ Patent Term Extension (PTE) approved in Japan for 2 patents related to TWYMEEG®, extending the product patent life until 2036 ➡️ Exclusive discussions being finalized with a leading investor to monetize royalties from sales of TWYMEEG® (Imeglimin) in Japan ➡️ As of June 30, 2024, cash and cash equivalents amounted to EUR 2.8 million (USD 3 million) ➡️ Cash horizon estimated to be sufficient until the completion of the transaction, including only the tranches already drawn down or fully available under the equity-linked financing facility with IRIS ➡️ Rescheduling of the Annual General Meeting 2024, subject to the publication of the full-year results for the year ended December 31, 2023 For more information, read the press release: https://lnkd.in/eKVjR3Az

Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update : ➡️ TWYMEEG® gross sales in Japan for Sumitomo Pharma Fiscal Year 2023 reached JPY 4.6 billion (EUR 27.9 million), exceeding guidance by more than 8% ➡️ TWYMEEG®’s FY 2024 forecast of JPY 11.3 billion (EUR 69.1 million) would represent a 150% increase over FY2023 sales ➡️ Exclusive advanced discussions with a leading investor to monetize royalties from sales of TWYMEEG® in Japan ➡️ As of March 31, 2024, cash and cash equivalents were EUR 2.5 million (USD 2.7 million) ➡️ Cash runway until transaction closing, including tranches already drawn or fully available on the equity-linked financing facility with IRIS For more information, read the press release: https://lnkd.in/eueQNCt7

Poxel published its cash and revenue for the Full Year 2023 and Provides Corporate Update: ➡️ TWYMEEG® sales continue to perform well in Japan with 22.4 M€ total sales over the first 3 quarters of 2023 ➡️ The Company remains focused on securing additional financing to execute its strategic plan in rare diseases For more information, read the press release: https://lnkd.in/eDPC6zEk

Today is #worlddiabetesday . In 2023, the campaign focuses on the importance of knowing risks of type 2 diabetes to help delay or prevent the condition and highlighting the impact of diabetes-related complications and the importance of having access to the right information and care to ensure timely treatment and management. To learn more about this day https://lnkd.in/dcJMsBe And to learn more about Poxel's commercialized drug treating T2D, TWYMEEG (Imeglimin) : https://lnkd.in/gH9Zb_9A

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

COM:POXELPHARMA

Poxel SA

Last Close

0.26

13/11 10:53

Market Cap

22.74M

Beta: -

Volume Today

207.75K

Avg: -

Analysis Not Available